Comparison · NCT01446809-7aa78352
Arm I (Pazopanib Hydrochloride) vs Arm II (Placebo): Progression Free Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Pazopanib Hydrochloride) vs Arm II (Placebo): Progression Free Survival. Trial comparisons, record NCT01446809-7aa78352. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01446809-7aa78352
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.714 | 0.454 | 0.883 | wilson | |
| Risk in group 2 | 0.571 | 0.25 | 0.842 | wilson | |
| Risk difference, group 1 minus group 2 | 0.143 | -0.233 | 0.505 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.25 | 0.607 | 2.57 | log | |
| Odds ratio, group 1 over group 2 | 1.88 | 0.282 | 12.5 | log | |
| Number needed to treat, for one more participant with the outcome on Arm I (Pazopanib Hydrochloride) than on Arm II (Placebo) | 7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Pazopanib Hydrochloride) | Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~Doxorubicin Hydrochloride: Given IV~External Beam Radiation Therapy: Undergo external beam radiation therapy~Ifosfamide: Given IV~Laboratory Biomarker Analysis: Correlative studies~Pazopanib Hydrochloride: Given PO~Pharmacological Study: Correlative studies~Therapeutic Conventional Surgery: Undergo surgery | 10 | 14 | OG000 |
| Group 2 | Arm II (Placebo) | Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~Doxorubicin Hydrochloride: Given IV~External Beam Radiation Therapy: Undergo external beam radiation therapy~Ifosfamide: Given IV~Laboratory Biomarker Analysis: Correlative studies~Pharmacological Study: Correlative studies~Placebo: Given PO~Therapeutic Conventional Surgery: Undergo surgery | 4 | 7 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Progression Free Survival
- Description
- Defined as the duration of time from randomization to progressive disease (per RECIST), local recurrence, distant metastatic disease (exclusive of stage IV subjects), or death, whichever occurs first.
- Time frame
- Up to 3 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
- NCT number
- NCT01446809
- Phases
- NA
- Conditions
- Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- Doxorubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
- Lead sponsor
- University of Washington
- Results first posted
- 2019-04-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01446809?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01446809-7aa78352